

**Guidelines Development Group
Biographies of proposed members
2023 WHO HBV Guidelines Update
April 2023**

Guidelines Development Group

Adelmounem Abdo

National Centre for Gastrointestinal and Liver Disease, Ibsina Gastroenterology Centre, Khartoum, Sudan

Dr Abdelmounem E Abdo is consultant physician and interventional gastroenterologist working at Ibsina Gastroenterology Centre, Khartoum Sudan. His field of interest is hepatitis, HCC, portal hypertension, ERCP, and small bowel endoscopy. He is the Director of the National Centre for Gastrointestinal and liver disease, vice president of the Sudanese society of gastroenterology; President-elect of the African and Middle East Association of Gastroenterology, and Secretary General of Pan Arab Association of gastroenterology.

Danjuma Adda

World Hepatitis Alliance, Nigeria

Danjuma K. Adda has a background in microbiology/virology, and an MPH, with over 15 years-experience in public health and advocacy. Danjuma is the current President, World Hepatitis Alliance (WHA), the first African to hold that position. He is also member of the WHO Strategic and Technical Advisory Committee on HIV, Viral Hepatitis and STIs (STAC-HHS). Danjuma is a leading voice for Hepatitis patients in Nigeria and uses his platform to advocate for the most vulnerable populations across Africa. He wants to change the narrative about Hepatitis and raise awareness about the deadliness of the disease. Danjuma was infected with Hep B while in clinical rotations and then lost his own mother to the disease several years later.

Suna Balkan

Médecins Sans Frontières, Paris, France.

Dr Balkan graduated with a medical degree from University Paris V, René Descartes in 1994 and Master of Public Health from University Paris VI in 1997. Dr Balkan has extensive field and technical expertise in infectious diseases, particularly viral hepatitis and decentralization of hepatitis C testing and cure in resource-limited settings. She authored several publications, including scientific articles published in peer-reviewed journals.

Ajeet Singh Bhadoria

All India Institute of Medical Sciences Rishikesh, India.

Dr Ajeet Singh Bhadoria is an academican and researcher at All India Institute of Medical Sciences Rishikesh, a pioneer medical institute in India. He is conducting regular capacity building workshops for physicians, lab technicians, and data entry operators in and running a Preventive Hepatology Clinic at All India Institute of Medical Sciences. Dr Bhadoria was Project Coordinator at WHO collaborating Centre in India and has collaborated with the WHO Country Office for India, SEARO and WHO headquarters in several important projects on sequelae surveillance, capacity building for nurses and physicians and non-invasive assessment of liver fibrosis. He has been involved in country's effort towards elimination of viral hepatitis for the past decade, instrumental to the advocacy efforts for the National Action Plan and National Viral Hepatitis Control Programme and implementation of the NVHCP in Uttarakhand State of India.

Yap Boum**Pasteur Institute of Bangui, Yaounde, Cameroon**

MPH, PhD, MBA

Executive Director at Pasteur Institute of Bangui

Professor Yap Boum II is the regional representative for Africa for Epicentre, the research arm of Médecins sans Frontières (MSF). He is currently based in Yaoundé, Cameroon. From 2009 to 2014 Boum headed the Epicentre research base in Mbarara, Uganda, leading research projects on tuberculosis and malaria among others. Most recently, in Guinea, he was in charge of Laboratory Coordination for the MSF/Epicentre Phase 3 trial for the vaccine against Ebola, VSV-EBOV.

Chari Cohen**Hepatitis B Foundation, United States of America**

Chari Cohen is President of the Hepatitis B Foundation and Professor at the Baruch S. Blumberg Institute. For the past 22 years, she has planned, implemented and evaluated community programs and research projects focusing on reducing health disparities and improving health outcomes associated with hepatitis B and liver cancer. Dr Cohen is co-chair of the national Hep B United coalition; co-founder and chair of CHIPO: Coalition Against Hepatitis for People of African Origin; co-chair of the Hep Free PA coalition; and chair of the Sidney Kimmel Cancer Center Community Advisory Board. She is a member of the ICE-HBV steering committee, the HepVu advisory committee, and is a member of the HBV Forum for Collaborative Research and the Patient Advocacy Group of the American Association for the Study of Liver Diseases (AASLD).

Maria Butí Ferret**Hospital Universitario Valle Hebrón, Universitat Autònoma de Barcelona Instituto Carlos III, European Association for the Study of the Liver (EASL)**

Dr Maria Butí Ferret is Professor of Medicine and Chief of Internal Medicine and Hepatology at the Hospital General Universitario Valle Hebrón, Barcelona, Spain. Dr Butí has worked in viral hepatitis for the last 25 years, with emphasis in diagnosis and treatment of hepatitis B and C. She has authored more than 450 papers in the field of hepatology, with numerous contributions to books. Dr Butí was President of the Spanish Association for the Study of Liver Diseases. She is and an active member of the American Association for the Study of Liver Diseases (AASLD) and EASL, and chair of Public Health and Policy and associate editor of the Journal of Hepatology. She participated in the expert panels of the EASL chronic hepatitis B guidelines and the Spanish Liver Association hepatitis B guidelines. She is a member of the one panel of the Spanish National Plan for Hepatitis C

Vladimir Chulanov**Reference Centre for Viral Hepatitis, I.M Sechenov First Moscow State Medical University, Russia**

Dr Vladimir Chulanov graduated from the Scientific Faculty of the I.M. Sechenov Moscow Medical Academy in 1995. In 2003 he attained his Ph.D. and in 2013 D.Sc. degree. Dr Chulanov worked at the Central Research Institute of Epidemiology. He headed Clinical Diagnostics and Research Center and Viral Hepatitis Reference Center. In 2014 Dr Vladimir Chulanov became a professor of the I.M. Sechenov First Moscow State Medical University, infectious diseases department, and since 2020 has been Deputy Director for Science and Innovations of the National Medical Research Center for TB and Infectious Diseases of the Ministry of Health of the Russian Federation. Under his leadership, a number of regulatory and methodological documents (sanitary rules, clinical guidelines), teaching aids, reference books were developed. He has led the development and implementation of laboratory diagnostic methods, the national register of viral hepatitis patients, and oversees an extensive research portfolio.

Naranbaatar Dashdorj**Onom Foundation, Ulaanbaatar, Mongolia**

Dr Naranjargal Dashdorj is one of the co-founders of Onom Foundation and has been Head of the Onom Foundation since June 2013. With her leadership, Onom Foundation has played a key role in shaping the Hepatitis Prevention, Control and Elimination Program of Mongolia (HPCE program). HPCE program aims to eliminate hepatitis C by 2020 and reduce liver cancer in Mongolia. The program was announced in September 2014 by Onom Foundation, Mongolian Society of Hepatology and Mongolian Gastroenterology Association. Later, in 2016 the HPCE program was adopted by the Mongolian Government. Nara holds a Degree in Medicine from Peking University Health Science Center, Beijing, China, and a Ph.D. from Nottingham University, Nottingham, United Kingdom. Dr Dashdorj was a fellow of the UNESCO-L'OREAL Young Women in Life Sciences at the School of Medical and Surgical Sciences, University of Nottingham, United Kingdom. She was one of the Stars in Global Health of Grand Challenges Canada. The Stars in Global Health program supports Bold Ideas with Big Impact.

Hailemichael Desalegn Mekonnen**St Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia**

Dr Hailemichael Desalegn graduated from medical school and specialty in Internal Medicine at Jimma University, Ethiopia. He completed a fellowship program in Gastroenterology/Hepatology in 2014 at Addis Ababa University, and in 2020, his PhD with an outstanding performance at Aklilu Lemma Institute of Pathobiology (ALIPB) on Tropical and Infectious Disease (TRID). The main focus of his PhD work was on non-invasive markers of liver fibrosis and simplified treatment program for Hepatitis B virus in Sub-Saharan Africa. He is currently working as an Associate Professor and Consultant Gastroenterologist/Hepatologist in St. Paul's Hospital Millennium Medical College. He has established and is a Director of Sub-Saharan Africa Gastroenterology ECHO clinic. With collaborators, Dr Hailemichael Desalegn has established one of the largest treatment cohorts for Hepatitis B in sub-Saharan Africa. Through this cohort, he has contributed key knowledge in the presentation, natural evolution, and treatment success for Hepatitis B in Ethiopia.

Manal Hamdy El-Sayed**Ain Shams University , Cairo, Egypt.**

Dr Manal El-Sayed is the Director of the Clinical Research Center (MASRI-CRC) and Professor of Pediatrics and co-supervisor of the viral hepatitis treatment center at Ain Shams University, Cairo, Egypt. Dr El-Sayed is also the clinical director of the National HCV Pediatric Treatment Programme and secretary general of the Egyptian Liver Care Society. She is a founding member of the Egyptian National Committee for Control of Viral Hepatitis (NCCVH) and has contributed to the establishment of a nationwide network of more than 100 specialized liver centres, providing treatment to more than 3 million people, collaborated to the development of the National Action Plan for Prevention and Control of Viral Hepatitis and co-supervised the nationwide screening programme for adults and children. From 2011 to 2015, Dr El-Sayed was Vice-Chair of WHO's Technical Advisory Group for Prevention and Control of Viral Hepatitis in Egypt. She is a member of the Global Accelerator for Pediatric Formulations (GAP-f), European Study of Liver Disease International Liver Foundation (EILF) and International Coalition for Elimination of hepatitis B (ICE-HBV) and has been appointed to the board of directors of the Global Hepatitis Fund (EndHep2030).

Jordan Feld**Toronto Centre for Liver Disease, Toronto General Hospital, University of Toronto, Canada**

Dr Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr Feld

focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Currently, Dr Feld holds the R. Phelan Chair in Translational Liver Research as a clinician-scientist at the Toronto Centre for Liver Disease in the Toronto General Hospital where he now leads a large clinical and translational research program focused primarily on viral hepatitis.

Saeed Sadiq Hamid

Aga Khan University, Karachi, Pakistan.

Dr Saeed Sadiq Hamid is a Professor at the Department of Medicine and Director of the Clinical Trials Unit at Aga Khan University, Karachi, Pakistan. He has served as Chair at the Department of Medicine from during 2008-2018. He trained in Medicine and Gastroenterology in the United Kingdom, and in Hepatology at University of Texas Southwestern Medical School, Dallas, United States. He was Vice-President of the Pakistan Society of Gastroenterology, President of the Pakistan Society for the Study of Liver Diseases (PSSLD) and member of the Executive Council of the Asian Pacific Association for the Study of the Liver (APASL) from 2006-2010. He is currently Chair of Hepatology Interest Group of the World Gastroenterology Organization. He chaired the WHO Guidelines Development Group for Hepatitis C in 2015 and 2017. He sits on Advisory Committees of the Coalition for Global Hepatitis Elimination (CGHE) and the Hepatitis Fund. He also serves as Co-Chair of Coalition to Eradicate Viral Hepatitis in Asia-Pacific (CEVHAP).

Jin-Lin Hou

Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China

Jin-Lin Hou, MD is the Chairman and Professor of the Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University. Professor Hou was the president of APASL from 2016-2017 and the immediate past president of Chinese Medical Association of Infectious Diseases from 2013-2016. Between 1993 and 1994, he received training in the Department of Medicine at St. Mary's Hospital Medical School in London, UK. Between 2000 and 2001, Professor Hou was a senior visiting Fellow at the Institute of Hepatology, London, UK. He has published more than 300 articles in both national and international journals, including Lancet Infectious Diseases, GUT, Hepatology, Journal of Hepatology, Science et al.

Saleem Kamili

Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Dr Saleem Kamili is Chief of the Laboratory Branch, Division of Viral Hepatitis at the US Centers for Disease Control and Prevention (CDC). He has been working for more than 20 years at CDC on various aspects of hepatitis viruses including pathogenesis, vaccine design and delivery and diagnostics. Dr Kamili received the Young Scientist Award and Himalayan Gold Medal during his graduate studies and was awarded the MS Balayan Medal for his contributions to the study of hepatitis E. Dr Kamili co-authored CDC's updated guidelines on testing for hepatitis C virus infection. He serves as Associate Editor of the Journal of Medical Virology and Journal of Clinical Virology and has his laboratory actively involved in improving viral hepatitis diagnostics globally, partnering with various international institutions in order to achieve such goal.

Patrick Kennedy

Queen Mary's University, London, United Kingdom

Professor Patrick Kennedy is a Consultant Hepatologist and Gastroenterologist at Barts Health NHS Trust. He graduated from University College Dublin and completed his post-graduate medical training in Gastroenterology and Hepatology in London. He was appointed as a Clinical Senior Lecturer in Hepatology at Barts and The London School of Medicine & Dentistry in 2009. Professor Patrick Kennedy's main clinical interests include viral liver disease; focusing on disease assessment and stratification using novel virological and immunological approaches. As an experienced hepatologist, Professor Kennedy manages all aspects of liver disease including alcohol, fatty liver disease and liver failure. He has a specialist interest in liver disease affecting young people and runs a dedicated young adult liver service at The Royal London Hospital. He also manages liver disease for professional sports people and elite athletes across the United Kingdom and abroad. He is the chief/principal investigator for a number of investigator-led and commercial phase 1, 2 and 3, clinical trials in HBV therapy.

Giten Khwairakpam**TREAT Asia/amFAR Bangkok, Thailand.**

Giten is currently the Community and Policy Program Manager at amFAR's TREAT Asia program in Bangkok, Thailand. He is a member of World Health Organization's Global Guidelines Development Group on hepatitis B and hepatitis C and a member of the Expert Advisory group on HCV with the Medicines Patent Pool. He also has served in different technical groups on viral hepatitis in WHO WPRO and SEARO region. He has been working on improving HIV and hepatitis C treatment access and advocating for price reductions in South and South East Asia in partnership with regional and national community networks. In 2017, the Economist Intelligence Unit profiled him as a Change Maker for hepatitis C.

Sulaiman Lakoh**University of Sierra Leone and Ministry of Health & Sanitation, Freetown, Sierra Leone**

Sulaiman Lakoh is a Sierra Leonean Physician with over eight years of work experience in the fields of Internal Medicine, Infectious Diseases and Public Health. He provides Technical Assessment and Capacity Development in HIV, TB, Cholera, Antimicrobial Resistance and Infection Prevention and Control. He graduated with a Bachelor of Medicine and Bachelor of Surgery degree from the University of Sierra Leone, Sulaiman is a Member of the West African College of Physicians and holds a certificate in Clinical Management of HIV from the University of Washington, and a Master of Public Health from the University of Central Nicaragua. Dr Lakoh is an early career researcher with an extensive knowledge and experience in the management, prevention and control of infectious diseases.

Maud Lemoine**Imperial College London and MRC Unit The Gambia, London, United Kingdom**

Dr Maud Lemoine is Professor and Honorary Consultant in Hepatology at St Mary's hospital, Imperial College London, UK. She completed her medical degree and PhD in Paris, France. She also graduated in political sciences from the Institute of Political Studies in Paris. Her research activities are mainly focused on the prevention and management of viral hepatitis in resource-limited countries, mainly in Africa. Since 2011, she has been working with the Medical Research Council (MRC) The Gambia unit, as part of the hepatitis B PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa) programme in The Gambia and Senegal. She has been member of the WHO guideline development group for the management of chronic hepatitis B/C and is regularly commissioned by the WHO viral hepatitis unit for external reviews and consultancies.

David Handojo Muljono

Eijkman Institute for Molecular Biology, Indonesia

Professor Muljono is a clinician who also works in the arena of basic biomedical research. He joined the Eijkman Institute for Molecular Biology in Jakarta in 1995 as the head of the hepatitis unit, and has been carrying out basic and translational researches in viral hepatitis. He is also actively involved in international and national activities targeted to public health in the prevention and control of viral hepatitis and emerging diseases. In 2014, he was a member of the WHO Strategic and Technical Advisory Committee in Hepatitis (STAC-Hep), and is now the Chairman of the National Expert Committee for Hepatitis. In 2011, Professor Muljono was inaugurated as the Academy Professor Indonesia in Hasanuddin University, Makassar.

Wongani Mzumara**HIV/AIDS and Viral Hepatitis Department, Ministry of Health, Lilongwe, Malawi**

Dr Mzumara obtained his medical degree from the Ryazan State Medical University in 2015, and completed his Masters in public Health and Masters in Family Medicine at the University of Edinburgh in 2020 and 2022 respectively. He currently works as Program Officer at the HIV/AIDS and Viral Hepatitis department of the Ministry of Health in Malawi

Edith Okeke**University of Jos / Jos Teaching Hospital, Jos, Nigeria**

Edith Okeke is Professor of Medicine in the Faculty of Medical Sciences, University of Jos, Nigeria where she heads the Gastroenterology / Hepatology unit of the Jos University Teaching Hospital, Jos. She trained in Gastroenterology/ Hepatology in the Jos University Teaching Hospital, completing a Fellowship of the West African College of Physicians in 1992. Professor Okeke is involved in national and international clinical research collaborations. She was the Principal investigator of the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) in Jos, a multi-country research project and also the principal investigator of 'The Presentation of HCC in Nigerian Patients', an NIH sponsored study with the Northwestern University, Chicago. She is currently co-leading U54 Epigenomic Biomarkers of HIV Associated Cancers in Nigeria, another NIH sponsored research.

Janus Ong**University of the Philippines, Manila, Philippines**

Janus Ong is a consultant gastroenterologist and transplant hepatologist, and holds a Clinical associate professor position at the University of Philippines. He obtained his Doctor of Medicine degree from the University Philippines, Manila, in 1993 and a Master in Public Health from Johns Hopkins Bloomberg School Public Health and Hygiene, Baltimore in 2004. He trained as a transplant hepatologist at the Fairfax Hospital, Virginia, 2001—2006.

Corina Pop**Department of Gastroenterology and Medical Oncology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania**

Corina Pop trained in internal medicine at Bucharest Emergency University Hospital and became the Chief Doctor of the department of Gastroenterology, Doctor Specialist in internal medicine, specialist in diabetes, nutrition and metabolic diseases, and Associate Professor within the University of Medicine and Pharmacy Carol Davila in 2008. In 2019, Dr Pop became the National Coordinator for the elaboration of National Program of Cancer Control (NPCC) on Operational Program Administrative Capacity at the Ministry of health, and since 2020 has been the Medical Director of University Emergency Hospital Bucharest.

Christian B Ramers**Global Hepatitis Program, Clinton Health Access Initiative (CHAI), San Diego, CA, United States.**

Dr Ramers is the Chief of Population Health at the Family Health Centers of San Diego (FHCSD), a large Federally Qualified Health Center (FQHC) system serving nearly 200 000 medically underserved individuals throughout San Diego county. He is board certified in Internal Medicine, Infectious Diseases, and Addiction Medicine, and is particularly interested in HIV, HBV, HCV, and service of medically underserved, immigrant, and refugee populations. He oversees HIV and HCV clinical and educational programmes. He co-chairs the California Chapter of the American Academy of HIV Medicine and has advocated for HIV, HCV and addiction care at the state level. Since 2018 he has served as the Senior Clinical Advisor for the Clinton Health Access Initiative's Global Hepatitis Program, working to eliminate HBV and HCV in seven partner countries in Asia and Africa.

Tânia Reuter**Federal University of Espirito Santo, Brazil**

Professor Reuter graduated in Medicine from the Federal University of Espírito Santo (1985). She obtained a Master in Infectious Diseases from the Federal University of Espírito Santo (2003) and PhD in Sciences in Gastroenterology from the University of São Paulo (2021). She is an adjunct professor at the Federal University of Espírito Santo and Infectious Disease consultant at the Cassiano Antônio Moraes University Hospital.

Cielo Yaneth Ríos-Hincapié**Ministry of Health and Social Protection, Colombia, Bogotá, Colombia.**

Dr Ríos-Hincapié is an experienced medical doctor, specialist in Administrative Health Management, with Masters in Public Health and in HIV. Dr Ríos-Hincapié has been working with the Ministry of Health and Social Protection of Colombia since 2013, leading the national hepatitis response on prevention, diagnosis, treatment and follow up of persons living with hepatitis B or C

Lewis Roberts**Mayo Clinic, Rochester, United States**

Dr Lewis R. Roberts is the Peter and Frances Georgeson Professor in Gastroenterology Cancer Research and Consultant in Gastroenterology and Hepatology at the Mayo Clinic, where he is Co-Principal Investigator of the Mayo Clinic Specialized Program of Research Excellence (SPORE) in Hepatobiliary Cancers.

His research focuses on molecular mechanisms of liver and biliary carcinogenesis; biomarkers for diagnosis of liver, bile duct and pancreas cancers; and prevention, diagnosis and treatment of hepatitis and liver cancer, with a particular interest in immigrant African communities in the USA as well as in Africa. He has authored over 450 articles, book chapters and letters, and co-edited the book "Evaluation and Management of Liver Masses". He serves as Chair of the Global Outreach and Engagement Committee of the American Association for the Study of Liver Disease (AASLD); as President of Africa Partners Medical, a non-profit organization focused on improving healthcare delivery in Africa through medical education, practical skills training, provision of medical equipment and supplies, and health advocacy; as President of the West Africa Institute for Liver and Digestive Diseases Foundation; and as a member of the Advisory Council for The Hepatitis Fund.

Wendy Spearman**University of Cape Town, South Africa**

Wendy Spearman is Head of the Division of Hepatology, Department of Medicine, Faculty of Health Sciences at the University of Cape Town. She is Head of the Liver and Liver Transplant clinics

at Groote Schuur Hospital. She completed her 2-year Hepatology Fellowship under Professors Ralph Kirsch and Simon Robson at the UCT/MRC Liver Research Centre in 1991 and obtained her PhD in 2008 from the University of Cape Town. She is actively involved in outreach Liver education programmes, was appointed by the International Association of Providers of AIDS Care to develop Training modules on the management of Hepatitis B for sub-Saharan Africa and is co-director of the Viral Hepatitis in sub-Saharan Africa ECHO clinic. She was appointed as the lead consultant for the National Guidelines on the management and prevention of viral hepatitis in South Africa. Her research interests include viral hepatitis, drug-induced liver injuries, liver transplantation and novel immunosuppressants.

Su Wang

Centre for Asian Health and Viral Hepatitis, St Barnabas Medical Centre, New York, United States

Su Wang, MD MPH is the Medical Director for the Chinese Medical Program at Cooperman Barnabas Medical Center. She is board certified in Internal Medicine and Pediatrics, and primarily specializes in Adult Primary Care. She received her Medical Degree from the University of Miami and her Masters in Public Health from Johns Hopkins University. Dr Wang completed her Internal Medicine and Pediatric residencies at Georgetown University Medical Center, and served as a fellow in the epidemic intelligence service for the Centers for Disease Control and Prevention (CDC). She is committed to Asian health and wellness, as well as the clinical identification and treatment of Hepatitis B (including infections in pregnancy).

Paediatric and Adolescent sub-group

Alasdair Bamford

UCL Great Ormond Street, Institute of Child Health, London, United Kingdom

Dr Alasdair Bamford is a consultant and specialty lead in paediatric infectious diseases at Great Ormond Street Hospital, and an Honorary Associate Professor at UCL Great Ormond Street Institute of Child Health.

Dr Bamford completed medical training at University of Cambridge and University College London in 2001. He completed training in paediatric infectious diseases at Great Ormond Street, St Mary's Hospital and Evelina London Children's Hospital. He was awarded an NIHR research training fellowship and completed a PhD on paediatric HIV immunology at Imperial College London in collaboration with the UCL Great Ormond Street Institute of Child Health. Dr Bamford also works for the MRC Clinical Trials Unit. He is clinical advisor to a number of international clinical trials and cohort studies relating to paediatric HIV and other childhood infections. He is the lead author on the Penta/EACS guidelines for treatment of paediatric HIV in Europe and other national and international guidelines relating to the care of children affected by infectious diseases.

Mei Hwei Chang

Department of Pediatrics, College of Medicine National Taiwan University and Children Hospital Taipei, Taiwan (China)

Chang Mei-hwei is a Taiwanese paediatric hepatologist. Chang graduated from the National Taiwan University (NTU) College of Medicine, completed fellowship training in paediatric gastroenterology at UCLA Health, and later returned to Taiwan, subsequently serving as a distinguished chair professor within NTU's Department of Paediatrics. Chang has researched hepatitis B vaccination, biliary atresia in infants, and led the Children's Liver Foundation. She was featured in the 2016 documentary Taiwan Revealed: Medical Elite. In 2013, Chang was awarded the TWAS Prize in Medical Science. The following year, she was elected an academican of Academia Sinica. Chang was elected to fellowship within The World Academy of Sciences in 2018.

Geoffrey M Dusheiko**University College London Medical School King's College Hospital, London, United Kingdom.**

Dr Geoffrey Dusheiko is an Emeritus Professor of Medicine at University College London School of Medicine and a consultant hepatologist at King's College Hospital, London, United Kingdom. He graduated from the University of Witwatersrand in South Africa. His fellowships were conducted at the Johannesburg Hospital Liver Unit, the National Institutes of Health, Bethesda MD, United States, and the University of Minnesota, Minneapolis, USA. He served as interim Deputy Director of the Blood Safety, HIV, viral hepatitis and STI Division of Public Health England in 2019. He is a member of EASL, AASLD and International Association for the Study of the Liver (IASL). He is a co-editor of Alimentary Pharmacology and Therapeutics and he has previously served on editorial boards for Hepatology, the Journal of Viral Hepatitis, Best Practice & Research: Clinical Gastroenterology, Gut, and the Journal of Viral Eradication. He has authored more than 500 scientific articles published in international peer-reviewed journals.

Giuseppe Indolfi**Paediatric and Liver Unit, Anna Meyer Children's University-Hospital of Florence
Florence, Italy**

Giuseppe Indolfi, MD, PhD is an Associate Professor of Paediatric and Liver Unit at Anna Meyer Children's University-Hospital of Florence, Italy. His research interests are Paediatrics, Paediatric Hepatology, Viral Hepatitis, Viral Infection, Liver Diseases, Vaccination, HIV and, Immunology of Infectious Diseases. He is the Chair of the Hepatology Committee of ESPGHAN (European Society for Paediatric Gastroenterology, Hepatology and Nutrition).

Simon Ling**Gastroenterology Hepatology and Nutrition, The Hospital For Sick Children, Toronto, Canada**

Dr Simon Ling graduated in medicine from the University of Edinburgh, Scotland and trained in paediatric gastroenterology in Glasgow, Scotland and SickKids Toronto. He worked initially as Consultant at the Royal Hospital for Sick Children in Glasgow and was then appointed to SickKids and the University of Toronto in 2003. Dr Ling served as Head of the Division of Gastroenterology, Hepatology and Nutrition (2015-2022) and previously as Director of the Paediatric Gastroenterology Training Program (2009 to 2014). He received the Department of Paediatrics' Richard Rowe Award for Clinical Excellence in Paediatric Medical Care in 2013, and the Canadian Liver Foundation 50th Anniversary Recognition Medal on behalf of the National Board of Directors of the Canadian Liver Foundation in 2019. Dr Ling's subspecialty interest is paediatric liver disease. He also maintains a broad interest and experience in paediatric gastroenterology and endoscopy. Dr Ling's clinical research activities aim to improve our ability to predict and manage the progression of chronic liver disease and its complications, focusing on children at risk of variceal bleeding, children with cystic fibrosis liver disease (CFLD), and children with chronic viral hepatitis. He collaborates in the CFLD Research Network and the Hepatitis B Research Network (HBRN).

Tammy Meyers**University of the Witwatersrand, Johannesburg, South Africa University of New South Wales (UNSW),
Sydney, Australia Sydney, Australia.**

Dr Tammy Meyers is a paediatrician from South Africa with a background in paediatric infectious diseases. Dr Meyers was at the forefront of the response to the paediatric HIV/AIDS epidemic in South Africa and established services and a clinical research site in Soweto, where she worked for almost 20 years. Dr Meyers joined the faculty of the School of Public Health and Primary Care at the Chinese University of Hong Kong in 2010 and worked with WHO and UNICEF in Asia, contributing to

development of the framework for Elimination of Mother to Child Transmission (EMTCT) of HIV, Syphilis and Hepatitis B. She worked with the Cambodian government to update paediatric HIV treatment guidelines and led a policy review on chronic viral hepatitis in selected Asian countries. In Australia, she works with the Population Child Health Research Group at UNSW. She serves on the Regional Advisory Group for the Australasian Society for HIV, Blood Born Viruses and Sexually transmitted infections (ASHM) and spearheads with WPRO a series of webinars on access to care for children and young people infected with viral hepatitis.

Fatima Mir

Aga Khan University, Karachi, Pakistan.

Dr Mir graduated as a medical doctor from Khyber Medical College, Peshawar, Pakistan in 1997 and specialized in paediatrics from the College of Physicians and Surgeons, Aga Khan University and Emory University, Atlanta, GA, United States. Dr Mir earned a Masters in Clinical Research in 2013. She is an Associate Professor and Supervisor for Clinical Training and Research Output of Postgraduate Trainees in Paediatrics and Fellows in the Paediatric Infectious Disease Programme. She co-authored the National Consolidated Guidelines for Prevention and Management of HIV in Adults and Children in Pakistan and several scientific articles and served as principal investigator in several research projects. She is a committee member for the WHO Paediatric Antiretroviral Working Group (PAWG) and Paediatric Working Group for Hepatitis (PWGH).

Delta co-infection sub-group

Will Irving

University of Nottingham, Nottingham, United Kingdom

Professor William L. Irving is a consultant clinical virologist at the Queen's Medical Centre, Nottingham, since 1990. He has extensive experience in the field of viral hepatitis and blood-borne viruses. He currently chairs the National Strategy Group for Viral Hepatitis, having previously chaired the Department of Health Expert Advisory Group on Hepatitis (AGH). He is a member of the Advisory Committee Safety of Blood, Tissues and Organs (SaBTO) which advises UK ministers and health departments on the most appropriate ways to ensure the safety of blood, cells, tissues and organs for transfusion/transplantation, and is currently chairing a SaBTO working group on transmission of hepatitis B virus from donors with occult infection. He is also a member of the National Institute for Health and Clinical Excellence Policy Development Group which produced UK guidance aimed at increasing testing for HBV and HCV infection.

Francesco Negro

University of Geneva, Geneva, Switzerland

Francesco Negro is Professor at the Departments of Medicine and of Pathology and Immunology of the University Hospitals of Geneva, Switzerland. He obtained his Medical Degree in 1982 at the University of Torino, Italy, where he also completed his postgraduate education in Gastroenterology. He was Visiting Scientist and then Assistant Professor at the Georgetown University School of Medicine, Rockville, MD, USA from 1986 to 1989, and Guest Researcher at the Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA in 1989. He was appointed Full Professor of the Faculty of Medicine, University of Geneva in 2014. His research interests focus on viral hepatitis, especially on the pathogenesis of metabolic alterations induced by the hepatitis C virus, i.e. steatosis and insulin resistance. More recently, he has participated into numerous collaborative works on epidemiology and public health issues related to viral hepatitis. He is also chairing the Swiss Hepatitis C

Cohort Study, and is member of the updating panels of the clinical practice guidelines for HCV of the EASL and of the World Health Organisation.

Cirley Maria de Oliveira Lobato

Faculdade de Medicina da Universidade Federal do Acre (UFAC), Brazil

Dr Lobato graduated in Medicine from the Federal University of Amazonas-Faculty of Health Sciences (1990), and specialised in Infectious Diseases from the Tropical Medicine Foundation of Amazonas (1993), and then obtained a Master's Degree in Medicine and Health from the Federal University of Bahia (2003) and PhD in Public Health from the University of São Paulo (2011). She is currently an infectologist at the State Secretariat of Acre since 1993, effective Professor at the Federal University of Acre in the Bachelor's Degree in Medicine and in the Postgraduate Program in Health Sciences in the Western Amazon. She has expertise in infectious diseases, working mainly on the following topics: western Amazonia, epidemiology, hepatitis B, Hepatitis C, Hepatitis delta, Intra-familial transmission, Dengue, Zika and Chikungunya. She is a member of the Acriana Academy of Medicine, the Brazilian Society of Infectology and the Brazilian Society of Hepatology.

Cihan Yurdaydin

University of Ankara, Ankara, Turkey

Cihan Yurdaydin specialized in Internal Medicine at the University of Ankara Medical School, Turkey, and is currently in the Department of Gastroenterology and Hepatology at Koç University Medical School in Istanbul. Professor Yurdaydin was an Editorial Board member of the Journal of Hepatology from 1995 to 2000 and has been Editor-in-Chief of The Turkish Journal of Gastroenterology from 1999 until December 2013. He was an Associate Editor for Liver International from 2010 to 2013. He has served in the Scientific Committee of EASL between 2000 and 2003 and as Education Councillor from 2013 to 2015. He has also served the World Gastroenterology Organization at various positions and was the President of this organization between 2017 and 2019.